Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy
- Sponsor
- University Medical Center Groningen
- Study ID
- NCT06726512
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Oral Cancer
- Oral Squamous Cell Carcinoma (OSCC)
- Osteosarcoma
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- XEOS AURA 10 — DEVICESurgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
Study Details
The primary endpoint is the assessment of the clinical value of a novel high-resolution mobile PET-CT scanner for intraoperative margin assessment in oral squamous cell carcinoma, soft tissue sarcoma and osteosarcoma surgery. The predicted margin status will be correlated with the margin status determined with histopathology.
Key Dates
- First listed
- Dec 10, 2024
- Start date
- Jan 31, 2025
- Status verified
- Dec 2024
- Primary completion
- Oct 31, 2025
- Completion
- Apr 30, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Other: 2 MBq 18F-FDGSubjects are intravenously administered with 2.0 MBq/kg 18F-FDG, standard tracer used to diagnose and stage the malignancy. After standard of care excision of the primary tumor, a high-resolution PET-CT imaging of the fresh surgical specimen will be performed.
Primary Outcome Measure
The primary endpoint is to determine the margin detection rates of a novel high-resolution mobile PET-CT for intraoperative margin assessment in OSCC, STS, and OS surgery. [ Time Frame: Postoperatively i.e. 7-10 working days ]
Central Contacts
- Jasper Vonk, Dr.+31 50 36162029
Related Studies
- Clinical Orthopaedic Data Bank (Acute and Chronic)Recruiting · University of Florida · Gainesville, Florida
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentRecruiting · Children's Oncology Group · Birmingham, Alabama
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the TongueRecruiting · University of Michigan · Ann Arbor, Michigan